Suppr超能文献

新型辅酶Q10的抗糖尿病机制是其产生积极作用的基础:对胰岛素抵抗/糖尿病大鼠的胰岛素和脂联素受体、酪氨酸激酶、磷脂酰肌醇-3激酶、葡萄糖转运蛋白、可溶性晚期糖基化终末产物受体和内脂素的调节。

Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats.

作者信息

Amin Mohamed M, Asaad Gihan F, Abdel Salam Rania M, El-Abhar Hanan S, Arbid Mahmoud S

机构信息

Department of Pharmacology, Medical Division, National Research Center, Cairo, Egypt.

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

出版信息

PLoS One. 2014 Feb 20;9(2):e89169. doi: 10.1371/journal.pone.0089169. eCollection 2014.

Abstract

UNLABELLED

As a nutritional supplement, coenzyme Q10 (CoQ10) was tested previously in several models of diabetes and/or insulin resistance (IR); however, its exact mechanisms have not been profoundly explicated. Hence, the objective of this work is to verify some of the possible mechanisms that underlie its therapeutic efficacy. Moreover, the study aimed to assess the potential modulatory effect of CoQ10 on the antidiabetic action of glimebiride. An insulin resistance/type 2 diabetic model was adopted, in which rats were fed high fat/high fructose diet (HFFD) for 6 weeks followed by a single sub-diabetogenic dose of streptozotocin (35 mg/kg, i.p.). At the end of the 7(th) week animals were treated with CoQ10 (20 mg/kg, p.o) and/or glimebiride (0.5 mg/kg, p.o) for 2 weeks. CoQ10 alone opposed the HFFD effect and increased the hepatic/muscular content/activity of tyrosine kinase (TK), phosphatidylinositol kinase (PI3K), and adiponectin receptors. Conversely, it decreased the content/activity of insulin receptor isoforms, myeloperoxidase and glucose transporters (GLUT4; 2). Besides, it lowered significantly the serum levels of glucose, insulin, fructosamine and HOMA index, improved the serum lipid panel and elevated the levels of glutathione, sRAGE and adiponectin. On the other hand, CoQ10 lowered the serum levels of malondialdehyde, visfatin, ALT and AST. Surprisingly, CoQ10 effect surpassed that of glimepiride in almost all the assessed parameters, except for glucose, fructosamine, TK, PI3K, and GLUT4. Combining CoQ10 with glimepiride enhanced the effect of the latter on the aforementioned parameters.

CONCLUSION

These results provided a new insight into the possible mechanisms by which CoQ10 improves insulin sensitivity and adjusts type 2 diabetic disorder. These mechanisms involve modulation of insulin and adiponectin receptors, as well as TK, PI3K, glucose transporters, besides improving lipid profile, redox system, sRAGE, and adipocytokines. The study also points to the potential positive effect of CoQ10 as an adds- on to conventional antidiabetic therapies.

摘要

未标记

作为一种营养补充剂,辅酶Q10(CoQ10)此前已在多种糖尿病和/或胰岛素抵抗(IR)模型中进行了测试;然而,其确切机制尚未得到深入阐明。因此,本研究的目的是验证其治疗效果背后的一些可能机制。此外,该研究旨在评估CoQ10对格列美脲抗糖尿病作用的潜在调节作用。采用胰岛素抵抗/2型糖尿病模型,大鼠喂食高脂肪/高果糖饮食(HFFD)6周,随后腹腔注射单次亚致糖尿病剂量的链脲佐菌素(35 mg/kg)。在第7周结束时,动物用CoQ10(20 mg/kg,口服)和/或格列美脲(0.5 mg/kg,口服)治疗2周。单独使用CoQ10可对抗HFFD的影响,并增加肝脏/肌肉中酪氨酸激酶(TK)、磷脂酰肌醇激酶(PI3K)和脂联素受体的含量/活性。相反,它降低了胰岛素受体亚型、髓过氧化物酶和葡萄糖转运蛋白(GLUT4;2)的含量/活性。此外,它显著降低了血清葡萄糖、胰岛素、果糖胺和HOMA指数水平,改善了血清脂质谱,并提高了谷胱甘肽、sRAGE和脂联素的水平。另一方面,CoQ10降低了血清丙二醛、内脂素、ALT和AST水平。令人惊讶的是,除了葡萄糖、果糖胺、TK、PI3K和GLUT4外,CoQ10在几乎所有评估参数上的效果都超过了格列美脲。将CoQ10与格列美脲联合使用可增强后者对上述参数的作用。

结论

这些结果为CoQ10改善胰岛素敏感性和调节2型糖尿病紊乱的可能机制提供了新的见解。这些机制包括调节胰岛素和脂联素受体,以及TK、PI3K、葡萄糖转运蛋白,此外还改善了脂质谱、氧化还原系统、sRAGE和脂肪细胞因子。该研究还指出了CoQ10作为传统抗糖尿病疗法附加剂的潜在积极作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/3930675/d6888de19d75/pone.0089169.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验